Earnings summaries and quarterly performance for Vir Biotechnology.
Executive leadership at Vir Biotechnology.
Board of directors at Vir Biotechnology.
Research analysts who have asked questions during Vir Biotechnology earnings calls.
Patrick Trucchio
H.C. Wainwright & Co.
4 questions for VIR
Also covers: ALT, ARWR, ATAI +13 more
PN
Philip Nadeau
TD Cowen
4 questions for VIR
Also covers: ADVM, APLS, ATRA +13 more
HW
Huidong Wang
Barclays
3 questions for VIR
Also covers: ALNY, BCRX, BEAM +15 more
Joseph Stringer
Needham & Company
3 questions for VIR
Also covers: APLS, CDTX, LXRX +3 more
KC
Kyuwon Choi
Goldman Sachs
3 questions for VIR
Also covers: AMRN, ASND, BHVN +9 more
Alec Stranahan
Bank of America
2 questions for VIR
Also covers: AGIO, ALEC, BTAI +11 more
AN
Avraham Novick
Morgan Stanley
2 questions for VIR
Also covers: GUTS
NG
Nikola Gasic
Leerink Partners
2 questions for VIR
Also covers: CYTK
AT
Alex Tranehan
Bank of America
1 question for VIR
AM
Ali Mohammed
Leerink Partners
1 question for VIR
AN
Avi Nova
Morgan Stanley
1 question for VIR
Also covers: IONS
Billy
JPMorgan Chase & Co.
1 question for VIR
Eric Joseph
JPMorgan Chase & Co.
1 question for VIR
Also covers: BEAM, BLUE, ENTA +9 more
Hang Hu
Barclays
1 question for VIR
Also covers: NTLA
MU
Michael Ulz
Morgan Stanley
1 question for VIR
Also covers: ALNY, ARWR, FATE +8 more
PC
Paul Choi
Goldman Sachs
1 question for VIR
Also covers: AMRN, ARVN, ASND +12 more
RR
Rona Ruiz
Leerink Partners
1 question for VIR
RD
Ronny Dvir
JPMorgan Chase & Co.
1 question for VIR
Sean McCutcheon
Raymond James
1 question for VIR
Also covers: BMY, CMPX, CRIS +6 more
Recent press releases and 8-K filings for VIR.
Vir Biotechnology Provides Clinical Pipeline Updates and Financial Outlook
VIR
New Projects/Investments
Guidance Update
- Vir Biotechnology's tobevibart + elebsiran combination therapy for Chronic Hepatitis Delta (CHD) demonstrated 88% HDV RNA TND (target not detected) at Week 96 in the Phase 2 SOLSTICE trial, significantly outperforming monotherapy. Upcoming clinical milestones include 72 & (partial) 96-week SOLSTICE data in January 2026 and topline data for ECLIPSE 1, 2, and 3 trials in 4Q 2026 and 1Q 2027.
- The company's oncology pipeline, featuring masked T-cell engagers (TCEs), showed promising early Phase 1 results: VIR-5500 (PSMA) achieved 100% PSA decline and 58% PSA50 responses, while VIR-5818 (HER2) demonstrated 50% observed tumor shrinkage in 10 out of 20 patients with a 65% disease control rate in HER2+ solid tumors, both with tolerable safety profiles.
- Vir Biotechnology reported approximately $781 million in cash and investments as of December 31, 2025, providing a cash runway into Q4 2027.
- A strategic collaboration with Norgine for tobevibart + elebsiran in Europe, Australia, and New Zealand includes an €55 million initial reimbursement and potential for up to €495 million in milestones.
Jan 14, 2026, 11:45 PM
Vir Biotechnology Provides Update on Hepatitis Delta Program and Oncology Pipeline at J.P. Morgan Healthcare Conference
VIR
New Projects/Investments
Guidance Update
Product Launch
- Vir Biotechnology's lead program for chronic hepatitis Delta, a combination of Tobevibart and elebsiran, demonstrated 88% HDV target not detected at 96 weeks in Phase II Solstice trial data. Initial top-line data from the Phase III Eclipse program is anticipated in Q4 2026, with further data in Q1 2027.
- The company entered a commercial license agreement with Norgine for its hepatitis Delta program in Europe, Australia, and New Zealand, which includes an upfront payment of EUR 550 million in milestone payments and royalties, and contributes to funding the Eclipse program.
- Vir is progressing a clinical-stage oncology pipeline of dual-mask T-cell engagers, with an update on VIR-5500 (PSMA-targeted) expected in Q1 2026.
- The company has extended its cash runway into Q4 2027, enabling it to cover major clinical milestones and prepare for the commercial launch of its hepatitis Delta program.
Jan 14, 2026, 11:45 PM
Vir Biotechnology Provides Updates on Hepatitis Delta Program, Oncology Pipeline, and Cash Runway
VIR
New Projects/Investments
Guidance Update
Product Launch
- Vir Biotechnology is advancing its lead program for chronic hepatitis Delta, with a Phase III registration program (ECLIPSE) underway and initial top-line data expected in Q4 2026 and Q1 2027. A commercial license agreement with Norgine for Europe, Australia, and New Zealand was announced, including an upfront payment of EUR 550 million in milestone payments.
- The company's oncology pipeline includes clinical-stage dual-masked T-cell engagers, with updated safety and efficacy data for VIR-5500 (PSMA-targeted) anticipated in Q1 2026.
- Vir Biotechnology has extended its cash runway into Q4 2027, which is expected to cover major clinical inflection points and preparation for the commercial launch of its hepatitis Delta program.
Jan 14, 2026, 11:45 PM
Vir Biotechnology Provides Pipeline Updates and Extends Cash Runway
VIR
New Projects/Investments
Guidance Update
- Vir Biotechnology's lead program for chronic hepatitis Delta, a combination regimen of Tobevibart and elebsiran, is in a Phase III registration program (Eclipse) with potential regulatory review in 2027. Initial top-line data for the Eclipse studies are anticipated in Q4 2026 and Q1 2027.
- The company announced a commercial license agreement for its hepatitis Delta program with Norgine, including EUR 550 million in upfront and milestone payments and healthy royalties on sales, while retaining commercialization rights in the U.S. and other key markets.
- Vir is advancing a clinical-stage pipeline of dual-masked T-cell engagers for solid tumors, with updated safety and efficacy data for VIR-5500 (PSMA-targeting T-cell engager) expected in Q1 2026 (February).
- The company has extended its cash runway into Q4 2027, supported by the Norgine collaboration and disciplined resource deployment, covering major clinical inflection points and commercial launch preparation for the hepatitis Delta program.
Jan 14, 2026, 11:45 PM
Vir Biotechnology Provides Q4 2025 Financial Update and Clinical Milestones
VIR
Guidance Update
New Projects/Investments
- Vir Biotechnology reported an estimated cash and investments balance of approximately $781 million as of December 31, 2025, extending its cash runway into Q4 2027 due to a Norgine licensing agreement and disciplined resource deployment.
- Positive updated Phase 2 SOLSTICE data for chronic hepatitis delta (CHD) showed the combination of tobevibart and elebsiran achieved undetectable HDV RNA in 88% of participants evaluable at 96 Weeks of treatment, compared to 46% for monotherapy. Topline data from the Phase 3 ECLIPSE 1 trial is expected in Q4 2026, with ECLIPSE 2 and ECLIPSE 3 data anticipated in Q1 2027.
- New Phase 1 data for PSMA-targeted VIR-5500 in prostate cancer will be presented at the 2026 ASCO Genitourinary Cancers Symposium in February. Phase 1 dose escalation response data for VIR-5818 in HER2-expressing solid tumors are also expected in the second half of 2026.
Jan 12, 2026, 1:07 PM
Vir Biotechnology Reports Year-End 2025 Cash and Clinical Program Updates
VIR
Guidance Update
New Projects/Investments
- Vir Biotechnology reported an unaudited year-end 2025 cash and investments balance of approximately $781 million, with its cash runway extended into Q4 2027 due to a licensing agreement and continued financial discipline.
- Positive, updated Phase 2 SOLSTICE data for chronic hepatitis delta (CHD) showed the combination of tobevibart and elebsiran achieved undetectable HDV RNA in 88% of participants evaluable at 96 Weeks of treatment.
- The company expects topline data from the Phase 3 ECLIPSE 1 trial in Q4 2026 and will present new Phase 1 data for its PSMA-targeted VIR-5500 in prostate cancer in February 2026.
Jan 12, 2026, 1:00 PM
Vir Biotechnology Updates on 2025 Clinical Progress and Future Milestones
VIR
New Projects/Investments
Guidance Update
- Vir Biotechnology reported promising early results in January 2025 for its masked T-cell engager programs, Vir-5500 (PSMA CD3) and Vir-5818 (HER2 CD3).
- An update on the Vir-5500 PSMA program is anticipated in Q1 2026, which will include safety, efficacy (PSA 50s, PSA 90s, durability), and RECIST data from monotherapy dose escalation in late-line patients.
- The company's Hepatitis Delta program's Phase 2 Solstice trial showed that 66% of patients achieved "target not detected" after 48 weeks of treatment.
- Enrollment for the Phase 3 Eclipse program for Hepatitis Delta is complete for Eclipse 1 (two months ahead of schedule), with a complete data set expected in Q1 2027.
Dec 3, 2025, 3:50 PM
Vir Biotechnology Highlights 2025 Clinical Program Achievements and Future Milestones
VIR
New Projects/Investments
- Vir Biotechnology achieved "focused and flawless execution" on its clinical programs in 2025, advancing three T cell engagers and its Hepatitis Delta registration program.
- The company reported "promising early results" in January 2025 for its masked T cell engagers, Vir-5500 (PSMA CD3) and Vir-5818 (HER2 CD3). Initial Vir-5500 data showed 58% of patients with PSA 50 and 8% with PSA 90 with low rates of CRS.
- An update for the Vir-5500 PSMA program is anticipated in Q1 2026, focusing on safety, PSA responses, durability, and RECIST data from monotherapy dose escalation in late-line patients.
- The Hepatitis Delta program's Phase 2 Solstice trial showed "transformative data," with 66% of patients achieving undetectable virus after 48 weeks of treatment. Enrollment for the Phase 3 Eclipse 1 trial was completed two months ahead of schedule, with a complete data set expected in Q1 2027.
Dec 3, 2025, 3:50 PM
Vir Biotechnology Provides Pipeline Update and Financial Outlook at Jefferies Healthcare Conference 2025
VIR
New Projects/Investments
Guidance Update
- Vir Biotechnology reported a strong financial position with $811 million in cash and investments at the end of the third quarter, providing a cash runway into mid-2027.
- The company is advancing multiple oncology programs, including VIR-5500 (PSMA-CD3 T-cell engager) for prostate cancer, with a comprehensive data set expected in the next quarter. Early data showed significant PSA declines and a favorable safety profile.
- In infectious diseases, their hepatitis delta program is in Phase 3 registrational trials, with Phase 2 SOLSTICE data demonstrating 66% of patients achieved target not detected after 48 weeks with monthly dosing, significantly outperforming the current market treatment. Top-line data for this program is anticipated in Q1 2027.
- Vir is actively exploring strategic partnerships for its hepatitis delta program outside the U.S. and for its T-cell engager programs.
Nov 18, 2025, 2:00 PM
Vir Biotechnology Highlights Strong Pipeline Progress and Cash Runway
VIR
New Projects/Investments
Guidance Update
- Vir Biotechnology reported a strong financial position with approximately $811 million in cash and investments at the end of the third quarter, providing a cash runway into mid-2027.
- The company is advancing its oncology pipeline, with a comprehensive data set for VIR-5500 (PSMA-CD3 T-cell engager) in prostate cancer expected in the next quarter. Early Phase 1 data showed promising efficacy, with 100% of patients at higher doses experiencing PSA decline and a favorable safety profile.
- In infectious disease, the Hepatitis Delta program is in Phase 3 registrational trials, with top-line data anticipated by Q1 2027. Phase 2 SOLSTICE trial data demonstrated 66% of patients achieved "target not detected" after 48 weeks with monthly dosing.
- The Hepatitis Delta program has received FDA Breakthrough and Fast Track designations, as well as EMA PRIME and Orphan Drug designations. Vir is actively pursuing strategic partnerships for this program outside the U.S. and for its T-cell engager programs.
Nov 18, 2025, 2:00 PM
Quarterly earnings call transcripts for Vir Biotechnology.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more